Symphony Financial Services Inc. Purchases 3,962 Shares of Pfizer Inc. $PFE

Symphony Financial Services Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 24.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,411 shares of the biopharmaceutical company’s stock after acquiring an additional 3,962 shares during the quarter. Symphony Financial Services Inc.’s holdings in Pfizer were worth $495,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter valued at about $27,000. Curio Wealth LLC raised its holdings in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer in the second quarter worth approximately $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the 1st quarter worth approximately $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $25.49 on Wednesday. The stock has a market cap of $144.93 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company’s 50 day moving average is $24.75 and its two-hundred day moving average is $24.41. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley reduced their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.18.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.